Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Down 5.13%
As of Monday, November 02, Clinuvel Pharmaceuticals Limited’s CUVL share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Michael Rose
Rosalio Madrigal
Michael Rose
Jenna Brashear
| Share Statistics | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $240.0 | $203.5 | 31% |
|
| Shares Out (Mil) | 35.2 | 55.2 | 40% |
|
| Institutional Ownership | 70.8% | 93.3% | 43% |
|
| Float (Mil) | 44.0 | 40.4 | 44% |
|
| Beta | 0.57 | 1.05 | 32% |
|
| Avg Daily Volume (000s) | 7 | 569 | 16% |
|
| Price Change (52-week) |
(42.9%) | 38.8% | 25% |
|
| Growth | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.4% | 13.6% | 66% |
|
| Net Income (5yr) | 4.9% | (10.7%) | 47% |
|
| EPS (5yr) | 4.9% | 15.4% | 39 |
|
| Dividends (5yr) | 13.1% | 0.0% | 53% |
|
| Cash Flow (5yr) | (19.2%) | (15.7%) | 35% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $40 | 22% |
|
| Net Income (TTM) (Mil) | $24 | ($44) | 49% |
|
| EPS (TTM) | $0.469 | ($1.400) | 52% |
|
| Operating Cash Flow (TTM) (Mil) | $26 | ($35) | 42% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $-0 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $147 | $142 | 25% |
|
| Valuation | CUVL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.24 | 1.96 | 38% |
|
| P/E | 10.0 | 16.9 | 21% |
|
| Dividend Yield | 0.8% | 0.0% | 64% |
|
| PEG (5yr hist) | 2.0 | 0.9 | 71% |
|
| Ratios | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.2% | 67.6% | 90% |
|
| Net Margin | 36.1% | (50.8%) | 93% |
|
| ROA | 12.3% | (47.0%) | 90% |
|
| ROE | 13.5% | (51.8%) | 67% |
|
| Liabilities to Assets | 7.5% | 29.6% | 4% |
|
| F-Score | 4 | 3 | 33% |
|
Clinuvel Pharmaceuticals Limited did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors